CD276 and glioma: Gliomas of TrMRS high-risk group presented with significantly higher expression level of CD274 (PD-L1), CD276 (B7H3), HAVCR2 (TIM3), PD1 (CD279, PDCD1), and CD44 (Figure 9A).